Associate Professor Borislava Mihaylova
- Health Economics Research Centre
Borislava (Boby) Mihaylova is an Associate Professor and Senior Health Economist at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
HALLIDAY A. et al, (2019), For Presentation at the European Society of Cardiology on 2nd September 2019
Impact of achieving primary care targets in Type 2 diabetes on health outcomes and healthcare costs.
Keng MJ. et al, (2019), Diabetes Obes Metab
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int
Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs
Keng MJ. et al, (2019), DIABETIC MEDICINE, 36, 161 - 161
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415